Rezolute Inc
Research Rezolute Inc (RZLT) on Bullrun: market cap USD 469.50M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRZLT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 469.50M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 16.17M
- Free cash flow-USD 13.74M
Valuation Snapshot
latest market cap is USD 469.50M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 74.40M | -USD 69.08M | n/a | -0.98 | USD 94.11M | USD 1.62M | USD 162.13M |
| FY2024 | USD 0 | -USD 68.46M | -USD 57.37M | n/a | -1.33 | USD 70.40M | USD 2.23M | USD 121.00M |
| FY2023 | USD 0 | -USD 51.79M | -USD 44.63M | n/a | -1.01 | USD 16.04M | USD 2.48M | USD 116.17M |
| FY2022 | USD 0 | -USD 41.06M | -USD 39.62M | n/a | -2.32 | USD 150.41M | USD 188.00K | USD 149.47M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 469.50M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 225.49M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 296.62M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 39.23M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 76.23M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 74.36M | n/a | n/a | n/a |
About Rezolute Inc
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Rezolute Inc's market cap?
Rezolute Inc's market capitalization is USD 469.50M.
What does Rezolute Inc do?
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.